Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$1.40
+0.4%
$1.42
$1.03
$2.57
$278.71M1.221.51 million shs1.39 million shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$5.80
+16.7%
$6.16
$4.84
$12.38
$291.31M0.43204,891 shs303,790 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$6.99
+23.4%
$5.84
$4.58
$14.21
$350.21M1.92543,426 shs1.11 million shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.15
+0.4%
$1.24
$0.92
$22.50
$68.44M0.61328,073 shs76,070 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
+0.72%-7.33%+9.45%-34.43%-32.20%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-9.83%-15.23%-10.47%-38.30%-34.02%
Cryoport, Inc. stock logo
CYRX
Cryoport
+2.17%+1.43%+3.10%-19.26%-65.49%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-2.56%-17.69%+1.79%-24.00%-88.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
2.2187 of 5 stars
3.51.00.00.00.63.31.3
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
2.3165 of 5 stars
3.62.00.00.02.82.50.0
Cryoport, Inc. stock logo
CYRX
Cryoport
3.0021 of 5 stars
4.41.00.00.02.03.30.6
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.4404 of 5 stars
3.04.00.04.62.23.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
3.00
Buy$10.50652.69% Upside
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.25
Buy$22.75292.24% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.71
Moderate Buy$11.0057.48% Upside
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50380.35% Upside

Current Analyst Ratings Breakdown

Latest IGMS, AURA, ATAI, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/1/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
4/1/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $11.00
3/31/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/26/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$19.00
3/26/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/25/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$25.00
(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$308K904.92N/AN/A$1.47 per share0.95
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$4.58 per shareN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
$228.39M1.53$0.41 per share16.95$9.45 per share0.74
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M25.55N/AN/A$3.46 per share0.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%5/13/2025 (Estimated)
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$76.41M-$1.75N/AN/AN/AN/A-41.57%-36.43%5/8/2025 (Estimated)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.49N/AN/AN/A-70.08%-13.35%-6.43%N/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$246.42M-$3.24N/AN/AN/A-7,534.03%-155.42%-61.04%5/14/2025 (Estimated)

Latest IGMS, AURA, ATAI, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.19N/AN/AN/AN/AN/A
5/14/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41N/AN/AN/A$4.25 millionN/A
5/8/2025Q1 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.45N/AN/AN/AN/AN/A
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
3/24/2025Q4 2024
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.43-$0.52-$0.09-$0.52N/AN/A
3/17/2025Q4 2024
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million
3/6/2025Q4 2024
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 million
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
N/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
0.14
5.81
5.81
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
12.47
12.47
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.22
5.22

Institutional Ownership

CompanyInstitutional Ownership
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
28.41%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%

Insider Ownership

CompanyInsider Ownership
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
31.20%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5.40%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.10%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
57.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
80199.80 million115.45 millionOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5050.23 million47.25 millionNot Optionable
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02050.14 million44.44 millionOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19059.78 million25.57 millionOptionable

Recent News About These Companies

IGM Biosciences (IGMS) Gets a Hold from RBC Capital
Igm Biosciences
IGM Biosciences (IGMS) Receives a Hold from Bank of America Securities

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atai Life Sciences stock logo

Atai Life Sciences NASDAQ:ATAI

$1.40 +0.01 (+0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$1.38 -0.02 (-1.43%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$5.80 +0.83 (+16.70%)
Closing price 04:00 PM Eastern
Extended Trading
$6.09 +0.29 (+5.00%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$6.98 +1.33 (+23.41%)
Closing price 03:59 PM Eastern
Extended Trading
$6.98 0.00 (-0.07%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.14 +0.01 (+0.44%)
Closing price 03:59 PM Eastern
Extended Trading
$1.12 -0.02 (-2.18%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.